{"id":378926,"date":"2023-12-13T10:16:19","date_gmt":"2023-12-13T15:16:19","guid":{"rendered":"https:\/\/platohealth.ai\/after-decade-long-dispute-over-crispr-cas9-editas-strikes-deal-with-vertex-to-cash-in\/"},"modified":"2023-12-13T20:00:41","modified_gmt":"2023-12-14T01:00:41","slug":"after-decade-long-dispute-over-crispr-cas9-editas-strikes-deal-with-vertex-to-cash-in","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/after-decade-long-dispute-over-crispr-cas9-editas-strikes-deal-with-vertex-to-cash-in\/","title":{"rendered":"After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

F<\/span><\/span>or a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.<\/p>\n

Editas Medicine, the winner of that battle in the U.S., will now cash in.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy<\/a>, the sickle cell therapy approved last week<\/a>.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n